Clover Health Investments Corp

Explore how Clover Health insider sales reveal portfolio strategy—not a warning—while evaluating the company’s upside and risk.

Priest Brady Patrick’s recent 98k‑share sale at $3.52 fuels speculation about Clover Health’s insider confidence and its Medicare Advantage growth prospects.

CEO Toy Andrew’s recent Clover Health sales show a cautious, profit‑taking trend amid a 26% rally, sparking debate on future stock value.

Insightful look at Clover Health’s April insider sales—why a CEO’s tax‑cover trade matters, the company’s fertility‑plan strategy, and what investors should watch.

CEO Toy Andrew’s recent sale of 60,765 Clover Health shares, a routine tax‑withholding move, sparks debate but signals confidence amid a new women’s health plan launch.

Insider activity at Clover Health shows routine tax‑related sales by CEO Jamie Reynoso, confirming stable governance and no imminent stock‑price impact.

Insider buying signals a shift at Clover Health: CEO Patrick’s RSU purchase hints at long‑term confidence amid a low stock price and Medicare‑focused strategy.

Insider buys at Clover Health signal long‑term confidence amid a volatile market – see why CEO Jamie L.’s 159‑k‑share purchase could hint at a rebound.

CEO Jamie Reynoso’s recent insider sale of 5,833 Clover Health shares hints at cautious confidence as the stock faces a steep 48 % YTD decline, prompting investors to watch for future turnaround signals.

CEO Jamie Reynoso’s recent sale of 5,833 shares at $1.91 shows a strategic move amid Clover Health’s 48% YTD decline—investors should watch future Form 4 filings for insights on insider confidence and potential turnaround.